Everyone experiences nosebleeds at some point, but nosebleeds with no known cause can be a sign of hemophilia, according to ...

Over 5 years of treatment in hemophilia B patients, gene therapy research shows sustained factor IX activity and safety.

A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female ...

Some patients in England living with severe haemophilia B will soon be able to do away with need for regular infusions, after a weekly, subcutaneous shot from Pfizer was cleared for NHS use. The ...

CSL Behring has added another major European market to the list of those providing reimbursement coverage of its haemophilia B gene therapy Hemgenix, after agreeing an access deal in Germany. The ...

On World Haemophilia Day, Jens Oltrogge reviews the progress made in treating this rare disorder, which causes those with the disease to bleed because of a lack of sufficient clotting factor ...

The FDA has approved BioMarin Pharma’s Roctavian as the first gene therapy for haemophilia A, giving patients an alternative to regular injections of blood clotting factors or antibody therapies ...

Pfizer’s once-weekly antibody injection for haemophilia A and B, marstacimab, could be on track for regulatory approvals based on solid results in a phase 3 trial reported over the weekend ...

Novo Nordisk's anti-TFPI antibody concizumab has been backed for approval in the EU as a once-daily drug to prevent bleeding episodes in people with haemophilia. The recommendation by the EMA's ...

Learning to adapt to constant numbness and tingling in her hands has given columnist Cazandra Campos-MacDonald new insight into her sons.

Columnist G Shellye Horowitz shares the many miracles she's experienced in her life despite living with the bleeding disorder ...

CHMP has advised that Alhemo be approved for people with severe hemophilia A and moderate or severe hemophilia B without inhibitors.